SlideShare une entreprise Scribd logo
1  sur  63
Off Site PCI Expert Panel Review


        Primary PCI –
  Development and Outcomes
   of a New Paradigm of Care

          Thomas Wharton MD FACC FSCAI
                Exeter Hospital, Exeter, NH

                                              TPWharton
Limitations of Thrombolytic Agents

   Failure rate: 46% of patients receiving lytics are not
    reperfused well enough to improve survival (GUSTO).
   Recurrent Events: In 20% to 40% of patients.
   Strokes: In 1.4% to 6.3%.
   Contraindications: Only 25% to 33% of patients with acute
    M.I. may be eligible for thrombolytic therapy.
   Frequent Need for Subsequent Procedures: Cath, PTCA
   Are Given “Blindly”: Some patients will be treated
    unnecessarily, because they have either spontaneously
    reperfused or been mis-diagnosed.

    A few of these patients will bleed into the head.

                                                             TPWharton
PAMI-1 STUDY
PAMI-1 STUDY




    395 randomized lytic eligible pts with AMI :
 As compared with t-PA therapy for acute myocardial infarction,
  immediate PTCA reduced the combined occurrence of nonfatal
  reinfarction or death, was associated with a lower rate of intracranial
  hemorrhage, and resulted in similar left ventricular systolic function.
 NEJM 1993
  NEJM 1993
90-Minute Coronary Patency: PAMI vs GUSTO



  FLOW GRADE           PTCA (PAMI)   tPA (GUSTO)
 TIMI 0-1 (no flow)       6%           19%
 TIMI 2 (slow flow)        --          27%
 TIMI 3 (brisk flow)     94%           54%




                                             TPWharton
National Registry of Myocardial Infarction (NRMI)

     Only 35% of 241,000 AMI pts were treated with lytics.
     These lytic patients frequently needed other procedures:
          70.7% underwent cath later before discharge
          30.3%       “ PTCA
          13.3%       “   CABG


                   LYTICS (35%)      NO LYTICS (65%)
      Mortality            5.9%             13.0%
      Major bleeding       2.8%              0.5%

                                                          TPWharton
Primary PCI is Superior to
           Thrombolytic Therapy for Acute M.I.
         Pooled data from 10 randomized trials (n=2,606):


                                      Primary PTCA    tPA     p

value


  Mortality                           4.4 % 6.5 %     0.02

  Death or Reinfarction                  7.2 %       11.9 %
<0.001

  Total Stroke                           0.7 %        2.0 %
0.007
         Weaver, JAMA 1997;278:2093
  Hemorrhagic Stroke                     0.1 %        1.1 %   TPWharton
Primary PCI is Superior to
       Thrombolytic Therapy for Acute M.I.

Brand new pooled data from 21 randomized trials (n=7,739):
                                    Primary PCI   Lytic Rx   p value



 Mortality                          6.9 % 9.3 %    0.0002

 Reinfarction                          2.4 %       6.8%      <0.0001
 Total Stroke                          1.0 %       2.0 %      0.0004

 Hemorrhagic Stroke                   0.05 %       1.1 %     <0.0001

 Combined                              8.2         14.3      <0.0001



    Keeley, Lancet 2003;361:13-20
                                                                  TPWharton
Broader Applicability of Primary PCI

   Primary PTCA is arguably clinically superior to lytic therapy
    in lytic-eligible patients.*
                *Weaver, WD, JAMA 1997;278:2093

   But even if the therapies were equal, a majority of AMI patients are
    not candidates for lytic therapy, due to
         bleeding contraindications,
         shock,
         late presentation,
         prior bypass surgery,
         non-diagnostic EKG’s
                **Rogers WJ, AJM 1995;99:195

   This group is higher-risk than lytic-eligible patients.
    These patients need an alternative to "morphine and bed rest."
                                                                     TPWharton
Primary PCI vs. Other Treatments in Patients
Ineligible for Lytic Therapy (MITRA Registry)
                                     PTCA   Conservative or Fibrinolytic Therapy

                    High Bleeding                                 Non-Diagnostic EKG,
    50%              Risk (n=337)                50%             LBBB, Late Presentation
                                                                        (n=737)     42.3%




                                                % of Patients
    Mortality (%)




                             24.7%                                      24.1%

                                                                                 16.4%

                                                                 8.2%
                      2.2%

        0%                                            0%
                    PTCA Conservative                             Mortality     Combined Endpoint*
                         Therapy                                PTCA Lytic       PTCA Lytic

                                                                     *death, acute MI, stroke, CHF, angina

  Zahn, Catheter Cardiovasc Interv 1999;46:127 Zahn, Z Kardiol 1999;88:418
                                                                                                    TPWharton
Primary PCI in Lytic Eligible Pts that are
       High Risk (MITRA Registry)
High Risk Patients: Age >70, Anterior M.I., Heart Rate > 100

      16                   PCI            Lytics          15.6%


      12
                     9.8%

(%)     8
                                        6.7%

        4                                                            3.6%
                                                         4.1%
                  3.2%
                                     1.4%                          0.5%
        0
                Death          Reinfarction            Death or   Stroke
                                                        Re-MI
  O’Neill, J Invasive Cardiol 1998:10 Suppl A:4A-10A
                                                                            TPWharton
New Data From MITRA and MIR
             German Registries
 Pooled “real world” outcomes of nearly 10,000 AMI
 patients in 2 German Registries, 1994-1998:

                                 Primary PCI
    Thrombolysis
Mortality                            6.4%
    11.3%
  Primary angioplasty was associated with lower mortality in all
  subgroups both high- andodds ratio 0.54,including pts >75 y.o. 0.67
                           low-risk, 95% confidence interval 0.43 to

  As the mortality risk of the subgroup increased, the relative
  benefit of primary PCI increased.
  Zahn, JACC 2001;37:1827
                                                                TPWharton
Advantages of Primary PCI

   Can be used in virtually all infarct patients.
   Produces TIMI-3 flow over 90% of the time, not 54%.
   Does not cause intracranial bleeding.
   Reduces need for subsequent procedures (cath, PCI).
   Provides important angiographic information: patients
    who need urgent surgery can be detected early.
   Opens vessels as fast or faster.
   Can improve prognosis in cardiogenic shock.
   Yields a five-fold reduction in mortality in high-risk STEMI
    pts compared to thrombolytics.
                                                            TPWharton
Profiles of NRMI Registry Hospitals



 Medical School Affiliation

27.6%

 Cardiac Surgery

37.6%

 Cardiac Catheterization Laboratory
  Rogers WJ, Circulation 1994;90:2103
61.3%                                        TPWharton
DANAMI – 2 Trial: Primary PCI vs. Lytics
         at Hospitals With and Without PCI
                                 PCI On Site or After Transfer           Thrombolytic Therapy
                                                                                         14.2%
                       15%            13.7%
                                                                 12.3%
Primary Endpoint (%)
   (death, MI, CVA)




                       10%                                                      8.5%
                             8.0%
                                                      6.7%


                       5%




                       0%
                             All Patients            Presenting to            Presenting to
                                                     Angioplasty               Community
                                                        Centers                 Hospitals
                              (n = 1,572)               (n = 442)                (n = 1,129)
             Andersen, ACC 2002 Presentation
                                                                                                 TPWharton
Prague – 2 Trial
PRAGUE-2 Trial (Europe): Prospective randomization of 850 pts
 to lytic therapy on-site vs. emergency transfer for primary PCI
                          •Thrombolytic Therapy (n = 421)             Transfer for PCI (n = 429)
                                                                                         15.2%
             30-Day Mortality (%)




                                                            Death / MI / CVA (%)
                                          10.4%

                                    10%                                            10%           8.4%


                                                  6.0%




                                    0%                                             0%


   Immediate transport of all STEMI patients for PCI is now part of the
               national guidelines of the Czech Republic.
 Widimsky, European Society of Cardiology, September, 2002
                                                                                                        TPWharton
DANAMI-2 and PRAGUE-2

   The DANAMI-2 and PRAGUE-2 studies established
    primary PCI as the treatment of choice for all patients
    presenting with acute STEMI, regardless of where they
    initially present.
   All such patients at hospitals without PCI should be
    transferred immediately directly into the cath lab of a
    PCI center, ideally with an “indoor-outdoor” time of <30
    minutes.




                                                        TPWharton
Delay and Mortality of Primary PCI
               After T ransfer:
                             PTCA On Site (n=9,311)                        PTCA After Transfer (n=1,307)
                                         6.0h
                       6.0                                     10%

                                                                                         7.7%

                                 3.7h
        Time (hours)




                                                      Mortality (%)
                       4.0
                                                                                 5.0%
                                                                      5%

                       2.0




                       0.0                                            0%

                            Time From                                             Death
                         AMI Onset to PTCA                                    (In-Hospital)
Transfer of acute MI patients to a surgical institution involves risk and
   delay, and is associated with worse outcomes than PCI on site.
  Tiefenbrunn, Circulation 1997:96:I-531
                                                                                                           TPWharton
Guidelines Evolve as Medical Care Evolves

From the 1988 PCI Guidelines re Surgical Backup for PCI:
   “An experienced cardiovascular surgical team should
    be available within the institution for all angioplasty
    procedures,” and “there should be no exception
    to this requirement.”
   “All arrangements requiring transportation of patients
    to off-site surgical facilities fail to meet the necessary
    standards of care exercised by prudent physicians
    and cannot be condoned.”



                                                             TPWharton
Off Site PCI Expert Panel Review

             without onsite
                            surgery
        Primary PCI – ^
  Development and Outcomes
       n even newer
   of a New Paradigm of Care !
      a

          Thomas Wharton MD FACC FSCAI
                Exeter Hospital, Exeter, NH

                                              TPWharton
Primary Angioplasty for the Treatment of
          Acute Myocardial Infarction: Experience at Two
          Community Hospitals Without Cardiac Surgery
          Thomas P. Wharton, Jr., MD, FACC, Nancy Sinclair McNamara, RN, BSN,
          Frank A. Fedele, MD, FACC, Mark I. Jacobs, MD, FACC, Alan R. Gladstone, MD, Erik
          Funk, MD, FACC

          Exeter and Portsmouth, New Hampshire



      506 consecutive pts:
  “Primary angioplasty in patients with AMI can be performed safely
   and effectively in community hospitals without on-site cardiac
   surgery when rigorous program criteria are established.”

JACC April, 1999
 JACC April, 1999
2001 ACC/AHA Guidelines for Off-Site PCI

       The 2001 ACC/AHA guidelines designated primary PCI
       at hospitals with off-site cardiac surgery as Class IIb:
       “Usefulness/efficacy is less well established by
       evidence/opinion,” provided that:
        > 36 procedures/yr are performed at such hospitals,
        by higher-volume operators (>75 procedures/yr),
        within 90 ± 30 min of admission,
        with a proven plan for rapid access to a
             cardiac surgical center.


JACC 2001;37:2215                                             TPWharton
ACC/AHA 2001 PCI Guidelines
 ACC/AHA 2001 PCI Guidelines




                               TPWharton
2001 ACC/AHA Guidelines for Off-Site PCI


 This Committee also designated non-emergent PCI as
  Class III: stated that their Class III: “Not useful/effective,
  and in some cases may be harmful.”

 This classification was based on “consensus opinion of
  experts,” thus was not evidence-based
  (Level of Evidence C).




                                                            TPWharton
CRITICAL PATHWAY: PRIMARY PCI AT HOSPITALS WITH OFF-SITE CARDIAC SURGICAL BACKUP
                             PRE-HOSPITAL:
                               Suspected AMI.                                                                               Exeter Hospital
                                                                      Diagnostic
                      EMS paramedic level of care,
                aspirin, IV line, sublingual NTG, 12-lead
                                                                     ST elevation                                   ©2005 Wharton, Sinclair
                    ECG transmitted to ED, heparin.
                                                                           ED physician calls interventional
                     No diagnostic ST Elevation
                                                                             cardiologist and cath team.
                     EMERGENCY DEPARTMENT:
              AMI diagnosed. >30 minutes of uncontrolled
               ischemic pain with positive serum markers
            and/or ECG with >1mm of ST deviation or LBBB.
              Call interventional cardiologist and cath team.

             EMERGENCY DEPARTMENT TREATMENT:
           ASA (if not given by EMS), heparin or enoxaparin,
          IV beta blocker, nitropaste, morphine, second IV line.
            Consider platelet GP IIb/IIIa inhibitor, clopidogrel.
                  Treat pain, CHF, shock, arrhythmias.
                                                                                                      EMERGENCY TRANSFER
                                                                                                 to interventional / surgical hospital.
                               CATH LAB                                                      Activate Emergency Transfer Protocol
                                                                     No
                              AVAILABLE?                                                 with "indoor-outdoor" ED time goal of 45 minutes.
                                                                                                Consider IABP (at capable hospitals)
                                                                                                     if hemodynamically unstable.
                                    Yes

                                Consent,
                           transport to cath lab.


                          CARDIAC CATH LAB:                                                                                      PRIMARY PCI
           Arterial sheath; venous sheath if unstable or heart                                                                    of IRA only.
          block, IABP if in shock or hemodynamically unstable,
               pacer as needed. Coronary angiography.
                                                                                                                            Yes
                                                                                                                                                         No

                                                                              EMERGENCY CABG indicated
                            DETERMINE
                                                                                    with or without PCI:                          TIMI 3 FLOW
                        REVASCULARIZATION                           CABG
                                                                              Activate Emergency Transfer                           IN IRA?
                            STRATEGY
                                                                                         Protocol.



                               Primary PCI
                                                                                          RISK
                                                                                     STRATIFICATION*
Medical                                                                             AND MANAGEMENT
therapy
                              PRIMARY PCI                                                                  *Clinical and angiographic        Not
             of IRA only. Monitor ACT, GP IIb/IIIa inhibitor.                                              low risk: Age <70, 1-2 v        low risk
                Left ventriculogram. Consider right heart                                                  disease, EF >45%, no CHF
                                                                                           Low risk
                 catheterization, IABP, pacer if unstable.                                                 or arrhythmias, good PCI result.

                                                                                  Admit to interventional unit.                   Standard CCU care.
                                                                               Fast-track cardiac rehabilitation;                 Target discharge on
                          MEDICAL THERAPY                                      target discharge on hospital day                     hospital day 4-5,
          ASA, GP IIb/IIIa inhibitor, beta blocker, ACE inhibitor               3 without pre-discharge ETT.                          consider ETT.
           or ARB, statin, clopidogrel load and maintentance.                     Return to work at 2 weeks.                   Elective CABG if indicated.
             Smoking cessation,risk factor identification and
                  modification, cardiac rehabilitation.
                                                                           DISCHARGE; cardiac rehab phase II; ETT and lipid profile at 4 wks.
Circulation November 2005
 Circulation November 2005
                             T Wharton, Exeter Hospital
Primary PCI in 500 high-risk pts at 19 off-site hospitals was
 compared to pts transferred after presentation to non-PCI hospitals:
 “On-site PA and transfer groups had similar 30-day outcomes, and
 more rapid reperfusion for on-site PA.”
JACC 2004
 JACC 2004                                                       TPWharton
 “The study by Wharton et al. is extremely relevant because currently
   there is great debate regarding the appropriateness of performing
   primary PCI at hospitals without on-site surgery. . .”
 “This study documents that superb outcomes can be achieved at
   hospitals that do not offer on-site cardiac surgery. . .”

 JACC 2004
  JACC 2004                                                      TPWharton
 “I believe the data presented by Wharton et al. provide sufficient
   evidence to revise these guidelines to provide a class IIa indication
   (weight of evidence/opinion is in favor of usefulness/efficacy) for
   primary PCI at hospitals with catheterization laboratories but without
   on-site surgery.”


 JACC 2004
  JACC 2004                                                         TPWharton
2005 Guidelines for PCI Off-Site

 Nevertheless the 2005 Guidelines Committee
   maintained its Class IIb indication for Primary PCI at
   hospitals without on-site cardiac surgery.
 The 2005 Guidelines Committee also maintained its
   Class III indication for elective PCI at such hospitals,
   and unfortunately introduced new and very inflammatory
   language, arguably without valid justification, not citing
   a large amount of new literature:

   “Performing elective PCI in a setting without immediately
   available onsite cardiac surgery potentially compromises
   patient safety and is not recommended.”
                                                               TPWharton
TPW Presentation on Guidelines at ACC 2006


  “In view of the rapidly accumulating evidence
  of safety and efficacy, and no relevant evidence of harm
  reported to date (the JAMA Medicare claims-coding
  article notwithstanding),
  strong consideration should be given now to upgrading
  the Guidelines indication for non-emergent PCI from
  Class III to Class IIb at centers with off-site backup that
  can meet rigorous qualifications.”


                                                           TPWharton
TPW Presentation on Guidelines at ACC 2006

An audience member made the following observation at my
presentation at an ACC Guidelines session in 2006:

 “Since the Guidelines Writing Committee’s conclusions
    carry so much weight, and have such a powerful
  influence on 3rd party payors, state regulators, and
    litigation attorneys, the Writing Committee has a
    profound responsibility to fairly consider, fairly
    interpret, and rapidly update all of the available
        information in this vital and growing field.”

                                                    TPWharton
Critical Pathways in Cardiology June 2005
 Critical Pathways in Cardiology June 2005
1 Gathered facts and trends on prevalence of PCI without on-site surgery
 2 Reviewed existing guidelines worldwide on PCI without onsite surgery
 3 Reviewed literature related to PCI without on-site surgery much more
   comprehensively than did the 2005 ACC/AHA Guidelines
 4 Defined the best practice methods for PCI without on-site surgery
 5 Made recommendations on the role of PCI without on-site surgery
Catheterization and Cardiovascular Interventions March, 2007
 Catheterization and Cardiovascular Interventions March, 2007
Patient Selection Criteria – PRIMARY PCI

                 Patient Selection Criteria for Angioplasty and Emergency
                 Aortocoronary Bypass at Hospitals Without On-Site Cardiac Surgery

                 Avoid intervention in hemodynamically stable patients with:

                 • Significant (> 60%) stenosis of an unprotected Left Main (LM)
                   coronary artery upstream from an acute occlusion in the left
                   coronary system that might be disrupted by the angioplasty
                   catheter
                 • Extremely long or angulated infarct-related lesions with TIMI
                   grade 3 flow
                 • Infarct-related lesions with TIMI Grade 3 flow in stable patients
                   with three vessel disease
                 • Infarct-related lesions of small or secondary vessels
                 • Lesions in other than the infarct artery

                 Transfer for emergent aortocoronary bypass surgery patients with:

                 • High-grade residual left main or multivessel coronary disease and
                   clinical or hemodynamic instability
                       o After angioplasty or occluded vessels
                       o Preferably with intraaortic balloon pump support


                Table 16: American College of Cardiology/ American Heart Association Percutaneous
                Coronary Intervention Guidelines. Adapted with permission from Wharton TP Jr,
                McNamara NS, Fedele FA, Jacobs MI, Gladstone AR, Funk EJ. Primary angioplasty for
                the treatment of acute myocardial infarction: experience at two community hospitals
                without cardiac surgery. Journal of American College of Cardiology 1999; 33: 1257-65.

Catheterization and Cardiovascular Interventions March, 2007
 Catheterization and Cardiovascular Interventions March, 2007                                           TPWharton
Catheterization and Cardiovascular Interventions March, 2007
 Catheterization and Cardiovascular Interventions March, 2007   TPWharton
Catheterization and Cardiovascular Interventions March, 2007
 Catheterization and Cardiovascular Interventions March, 2007   TPWharton
Catheterization and Cardiovascular Interventions March, 2007
 Catheterization and Cardiovascular Interventions March, 2007   TPWharton
Catheterization and Cardiovascular Interventions March, 2007
 Catheterization and Cardiovascular Interventions March, 2007   TPWharton
TPWharton
Case Presentation

•   Two weeks before Hurricane Sandy this 59 y.o.
    lady lost her adult son tragically.
•   Two days after the son’s death, she collapsed
    at home.
•   Her husband, not knowing CPR, called 911 and
    ran to the neighbor’s house.
•   The neighbor ran over and started CPR.
•   EMS administered 3 shocks for ventricular
    fibrillation (VF), epinephrine boluses, performed
    intubation, and transmitted EKG to ED.

                                                        TPWharton
Case Presentation




                    TPWharton
Case Presentation

• After 30 minutes in the field, a pulse was felt.
• On arrival in the ED she was unresponsive,
  fixed pupils, with thready carotids and no
  peripheral pulse.
• A countershock was required for recurrent VF.
• The Arctic Sun therapeutic cooling system
  was applied in the E.D.




                                                     TPWharton
Arctic Sun Therapeutic Cooling Device




                                 TPWharton
Arctic Sun Therapeutic Cooling Device




                                 TPWharton
Updated 2005 AHA Guidelines for CPR




  Class II:   Conditions for which there is conflicting evidence and/or a divergence
              of opinion about the usefulness/efficacy of a procedure or treatment.
              IIa. Weight of evidence/opinion is in favor of usefulness/efficacy.
              IIb. Usefulness/efficacy is less well established by evidence/opinion.
                                               Circulation 2005; 112:IV-206 – IV-211
                                                                                       TPWharton
Case Presentation

•   She was then taken to the Cath Lab, shocky
    and very acidotic, on 2 pressors and
    the cooling device.
•   On arrival at the cath lab she developed
    pulseless electrical activity (PEA).
•   The Lucas cardiac compression device was
    applied, with a radiolucent back plate to allow
    fluoroscopy. This produced an excellent pulse.



                                                      TPWharton
LUCAS External Compression CPR




                            TPWharton
LUCAS External Compression CPR




                            TPWharton
Case Presentation
•   After bifemoral access we were able to use
    cranially-angluated fluoroscopy to position an
    intraaortic balloon while on the Lucas CPR device.
•   On the balloon pump and pressors, we were able
    to discontinue the Lucas CPR device.
•   Severe metabolic acidosis responded only poorly
    to aggressive treatment.
•   She remained unresponsive, pressor dependent.



                                                    TPWharton
Case Presentation



(Coronary angiography was shown which
 demonstrated a totally occluded proximal LAD
 artery with no antegrade flow and no
 collateralizaion, successfully recanalized with
 PCI/stenting.)




                                               TPWharton
Case Presentation

•   On reperfusion she developed incessant VF,
    requiring 7 countershocks, amiodarone boluses,
    empiric Mg++ and K+ IV.
•   She remained pressor and balloon pump
    dependent, acidotic, unresponsive, cardiac output
    1.6 L/m, wedge pressure 30mmHg, no urine.
•   After 18 h and the addition of dobutamine, her
    hemodyamics began to improve.
•   After 24 hours she was re-warmed.

                                                     TPWharton
Case Presentation




                    TPWharton
Case Presentation




                    TPWharton
Case Presentation

•   Pressors were weaned, IABP removed on day 3,
    extubated day 6.
•   Her echo EF had improved to 50-55% with
    minimal anterior wall hypokinesis.
•   By extubation on day 7 she was completely
    alert, very talkative.
•   One of the first things she said moments after
    extubation was that she had visited her
    deceased son; that he was “with God;” but God
    told her “get back home, I don’t want you yet.”
                                                      TPWharton
Case Presentation




                    TPWharton
Case Presentation

•   This extraordinary outcome demonstrates what
    a flawless “chain of survival” can accomplish,
    from EMS in the field, thru ED, thru respiratory
    and ICU nursing care.
•   In particular, this outcome would not have been
    possible without expert 24/7 PCI available
    nearby, at the point of first patient contact.
•   She is now home, enjoying Thanksgiving with
    her family, completely mentally intact and with
    excellent cardiac function.
                                                       TPWharton
Case Presentation

•   The door-to-defibrillation-to-cooling-to-
    Lucas CPR-to-balloon pump time
    (D-2-D-2-C-2-L-2-IABP time) was 86 minutes.
•   The LAD coronary was opened in 18m more.
•   Her brain was very poorly perfused for
    about 2 hours.
•   Locally available immediate primary PCI meant
    the difference between life and death in this
    woman.

                                                    TPWharton
Case Presentation

•   One of the cath lab staff observed after the
    procedure—and this was his own idea—


    “Ya know, Dr. Wharton, if we didn’t do so many
    stable elective patients in this lab, we wouldn’t
    have had the experience to be able to perform
    nearly so well in this case!”




                                                        TPWharton
2011 Guidelines for PCI Off-Site




                                   TPWharton
2011 Guidelines for PCI Off-Site

4.8. PCI in Hospitals Without On-Site Surgical

Backup: Recommendations

CLASS IIa

1. Primary PCI is reasonable in hospitals without onsite cardiac surgery, provided
that appropriate planning for program development has been accomplished.



CLASS IIb

1. Elective PCI might be considered in hospitals without on-site cardiac surgery,
provided that appropriate planning for program development has been
accomplished and rigorous clinical and angiographic criteria are used for proper
patient selection.




           Better Late than Never !!
                                                                                     TPWharton
Corazon Materials Related to
   Economic Quality Impact of
Avoidance of Staged PCI Procedures




           © Corazon, Inc. All rights reserved.
PCI-Staged vs. Same Setting of Care
           Payor Cost Avoidance Scenario                                                         $7302
                                                                                                 per case
                                                                                                   cost
             Sample based on 2010 Medicare
                                                                                                avoidance




                                                                                            $7+ Million
                                                                                           cost avoidance
                                                                                           with Statewide
                                                                                               Sample

•Hospital component for PCI based on CMS split of case volume across DRGs 246-251
•Physician Pro-fee for dx cath based on CMS left heart cath & PCI blended payment rate based on 1.4 stents/case
•Transport based on State ground rates + 10 miles & a blend of Advanced Life Support levels
                                      © Corazon, Inc. All rights reserved.

                                      © Corazon, Inc. All rights reserved.                                        64

Contenu connexe

Tendances

Amarelli 313 Transplantation Ii Early Graft Failure After Heart Transplant Le...
Amarelli 313 Transplantation Ii Early Graft Failure After Heart Transplant Le...Amarelli 313 Transplantation Ii Early Graft Failure After Heart Transplant Le...
Amarelli 313 Transplantation Ii Early Graft Failure After Heart Transplant Le...Cristiano Amarelli
 
@Cabg and mitral
@Cabg and mitral@Cabg and mitral
@Cabg and mitralescts2012
 
Troponin use it in all patients with acute heart failure! pro
Troponin use it in all patients with acute heart failure! proTroponin use it in all patients with acute heart failure! pro
Troponin use it in all patients with acute heart failure! prodrucsamal
 
Acs0605 Pulseless Extremity And Atheroembolism
Acs0605 Pulseless Extremity And AtheroembolismAcs0605 Pulseless Extremity And Atheroembolism
Acs0605 Pulseless Extremity And Atheroembolismmedbookonline
 
Pet ct assessment of therapeutic response in extra-nodal non Hodgkin lymphoma...
Pet ct assessment of therapeutic response in extra-nodal non Hodgkin lymphoma...Pet ct assessment of therapeutic response in extra-nodal non Hodgkin lymphoma...
Pet ct assessment of therapeutic response in extra-nodal non Hodgkin lymphoma...amr elsisy
 
Fdg thyroid nodule poster
Fdg thyroid nodule posterFdg thyroid nodule poster
Fdg thyroid nodule posterdeclen007
 
2014session5 3
2014session5 32014session5 3
2014session5 3acvq
 
Future of site stable to unstable
Future of site stable to unstableFuture of site stable to unstable
Future of site stable to unstableoptimacardio
 

Tendances (20)

Amarelli 313 Transplantation Ii Early Graft Failure After Heart Transplant Le...
Amarelli 313 Transplantation Ii Early Graft Failure After Heart Transplant Le...Amarelli 313 Transplantation Ii Early Graft Failure After Heart Transplant Le...
Amarelli 313 Transplantation Ii Early Graft Failure After Heart Transplant Le...
 
@Cabg and mitral
@Cabg and mitral@Cabg and mitral
@Cabg and mitral
 
Geri pres
Geri presGeri pres
Geri pres
 
Troponin use it in all patients with acute heart failure! pro
Troponin use it in all patients with acute heart failure! proTroponin use it in all patients with acute heart failure! pro
Troponin use it in all patients with acute heart failure! pro
 
Cardiac petct ahmed tawakol
Cardiac petct ahmed tawakolCardiac petct ahmed tawakol
Cardiac petct ahmed tawakol
 
2011 Annual Shareholder Meeting Presentation
2011 Annual Shareholder Meeting Presentation2011 Annual Shareholder Meeting Presentation
2011 Annual Shareholder Meeting Presentation
 
Triana
TrianaTriana
Triana
 
造影剤腎症
造影剤腎症造影剤腎症
造影剤腎症
 
Acs0605 Pulseless Extremity And Atheroembolism
Acs0605 Pulseless Extremity And AtheroembolismAcs0605 Pulseless Extremity And Atheroembolism
Acs0605 Pulseless Extremity And Atheroembolism
 
Tombal
TombalTombal
Tombal
 
Pet ct assessment of therapeutic response in extra-nodal non Hodgkin lymphoma...
Pet ct assessment of therapeutic response in extra-nodal non Hodgkin lymphoma...Pet ct assessment of therapeutic response in extra-nodal non Hodgkin lymphoma...
Pet ct assessment of therapeutic response in extra-nodal non Hodgkin lymphoma...
 
Minha S
Minha SMinha S
Minha S
 
01 primer hospital con angioplastía primaria sistemática c. real
01 primer hospital con angioplastía primaria sistemática c. real01 primer hospital con angioplastía primaria sistemática c. real
01 primer hospital con angioplastía primaria sistemática c. real
 
Lack of evidence in carotid stenosis
Lack of evidence in carotid stenosisLack of evidence in carotid stenosis
Lack of evidence in carotid stenosis
 
Estenosis Carotidea en paciente con Cardiopatía Isquémica
Estenosis Carotidea en paciente con Cardiopatía IsquémicaEstenosis Carotidea en paciente con Cardiopatía Isquémica
Estenosis Carotidea en paciente con Cardiopatía Isquémica
 
PCI in elderly patients
PCI in elderly patientsPCI in elderly patients
PCI in elderly patients
 
Fdg thyroid nodule poster
Fdg thyroid nodule posterFdg thyroid nodule poster
Fdg thyroid nodule poster
 
2014session5 3
2014session5 32014session5 3
2014session5 3
 
Statins+in+ACS
Statins+in+ACSStatins+in+ACS
Statins+in+ACS
 
Future of site stable to unstable
Future of site stable to unstableFuture of site stable to unstable
Future of site stable to unstable
 

En vedette

17 developing primary pci as a national reperfusion strategy for patients wit...
17 developing primary pci as a national reperfusion strategy for patients wit...17 developing primary pci as a national reperfusion strategy for patients wit...
17 developing primary pci as a national reperfusion strategy for patients wit...NPSAIC
 
Percutaneus coronary intervention in Non ST elevation myocardial infarction
Percutaneus coronary intervention in Non ST elevation myocardial infarctionPercutaneus coronary intervention in Non ST elevation myocardial infarction
Percutaneus coronary intervention in Non ST elevation myocardial infarctionRamachandra Barik
 
Ami Selayang Hospital
Ami Selayang HospitalAmi Selayang Hospital
Ami Selayang HospitalRashidi Ahmad
 
Trabajofinalgrupo 401117 4
Trabajofinalgrupo 401117 4Trabajofinalgrupo 401117 4
Trabajofinalgrupo 401117 4violeta_azul
 
Cờ Tướng - Liệt pháo tấn biên - Tập 1
Cờ Tướng - Liệt pháo tấn biên - Tập 1Cờ Tướng - Liệt pháo tấn biên - Tập 1
Cờ Tướng - Liệt pháo tấn biên - Tập 1Tran Tuan
 
FG GIP Lagos to Abuja
FG GIP Lagos to AbujaFG GIP Lagos to Abuja
FG GIP Lagos to Abujachan0496
 
Cờ Tướng - Các thế chiếu tướng
Cờ Tướng - Các thế chiếu tướngCờ Tướng - Các thế chiếu tướng
Cờ Tướng - Các thế chiếu tướngTran Tuan
 
Cờ Tướng - Pháo đầu đối phản cung mã
Cờ Tướng - Pháo đầu đối phản cung mãCờ Tướng - Pháo đầu đối phản cung mã
Cờ Tướng - Pháo đầu đối phản cung mãTran Tuan
 
Computer hoy ¡todo gratis! [367][26 octubre 2012][sfrd]
Computer hoy   ¡todo gratis! [367][26 octubre 2012][sfrd]Computer hoy   ¡todo gratis! [367][26 octubre 2012][sfrd]
Computer hoy ¡todo gratis! [367][26 octubre 2012][sfrd]Camilo Andrés Naranjo Murillo
 
Manifiesto por la transformación social
Manifiesto por la transformación socialManifiesto por la transformación social
Manifiesto por la transformación socialLiliam Guevara
 
QualityIndex - Software (www.datalink.inf.br)
QualityIndex - Software (www.datalink.inf.br)QualityIndex - Software (www.datalink.inf.br)
QualityIndex - Software (www.datalink.inf.br)datalinksoftwares
 
Cờ Tướng - Cờ tàn nghệ thuật và cờ thế giang hồ - Tập 1
Cờ Tướng - Cờ tàn nghệ thuật và cờ thế giang hồ - Tập 1Cờ Tướng - Cờ tàn nghệ thuật và cờ thế giang hồ - Tập 1
Cờ Tướng - Cờ tàn nghệ thuật và cờ thế giang hồ - Tập 1Tran Tuan
 
Cờ Tướng - Nủa đường liệt pháo
Cờ Tướng - Nủa đường liệt pháoCờ Tướng - Nủa đường liệt pháo
Cờ Tướng - Nủa đường liệt pháoTran Tuan
 
Cờ Tướng - Thiên phong pháo - 4 phần
Cờ Tướng - Thiên phong pháo - 4 phầnCờ Tướng - Thiên phong pháo - 4 phần
Cờ Tướng - Thiên phong pháo - 4 phầnTran Tuan
 
E-commerce services by Hermes NexTec
E-commerce services by Hermes NexTecE-commerce services by Hermes NexTec
E-commerce services by Hermes NexTecOleg Zhukov
 
Cờ Tướng - Cờ tướng khai cuộc cẩm nang
Cờ Tướng - Cờ tướng khai cuộc cẩm nangCờ Tướng - Cờ tướng khai cuộc cẩm nang
Cờ Tướng - Cờ tướng khai cuộc cẩm nangTran Tuan
 
Cờ Tướng - Cờ tướng trung cuộc
Cờ Tướng - Cờ tướng trung cuộcCờ Tướng - Cờ tướng trung cuộc
Cờ Tướng - Cờ tướng trung cuộcTran Tuan
 
Architektura nowoczesnej platformy analitycznej wspierającej kompleksowe zar...
Architektura nowoczesnej platformy analitycznej wspierającej kompleksowe zar...Architektura nowoczesnej platformy analitycznej wspierającej kompleksowe zar...
Architektura nowoczesnej platformy analitycznej wspierającej kompleksowe zar...Patryk Choros
 

En vedette (20)

17 developing primary pci as a national reperfusion strategy for patients wit...
17 developing primary pci as a national reperfusion strategy for patients wit...17 developing primary pci as a national reperfusion strategy for patients wit...
17 developing primary pci as a national reperfusion strategy for patients wit...
 
Percutaneus coronary intervention in Non ST elevation myocardial infarction
Percutaneus coronary intervention in Non ST elevation myocardial infarctionPercutaneus coronary intervention in Non ST elevation myocardial infarction
Percutaneus coronary intervention in Non ST elevation myocardial infarction
 
Ami Selayang Hospital
Ami Selayang HospitalAmi Selayang Hospital
Ami Selayang Hospital
 
Trabajofinalgrupo 401117 4
Trabajofinalgrupo 401117 4Trabajofinalgrupo 401117 4
Trabajofinalgrupo 401117 4
 
Cờ Tướng - Liệt pháo tấn biên - Tập 1
Cờ Tướng - Liệt pháo tấn biên - Tập 1Cờ Tướng - Liệt pháo tấn biên - Tập 1
Cờ Tướng - Liệt pháo tấn biên - Tập 1
 
FG GIP Lagos to Abuja
FG GIP Lagos to AbujaFG GIP Lagos to Abuja
FG GIP Lagos to Abuja
 
Cờ Tướng - Các thế chiếu tướng
Cờ Tướng - Các thế chiếu tướngCờ Tướng - Các thế chiếu tướng
Cờ Tướng - Các thế chiếu tướng
 
Mill andbrew
Mill andbrewMill andbrew
Mill andbrew
 
Cờ Tướng - Pháo đầu đối phản cung mã
Cờ Tướng - Pháo đầu đối phản cung mãCờ Tướng - Pháo đầu đối phản cung mã
Cờ Tướng - Pháo đầu đối phản cung mã
 
Computer hoy ¡todo gratis! [367][26 octubre 2012][sfrd]
Computer hoy   ¡todo gratis! [367][26 octubre 2012][sfrd]Computer hoy   ¡todo gratis! [367][26 octubre 2012][sfrd]
Computer hoy ¡todo gratis! [367][26 octubre 2012][sfrd]
 
Manifiesto por la transformación social
Manifiesto por la transformación socialManifiesto por la transformación social
Manifiesto por la transformación social
 
QualityIndex - Software (www.datalink.inf.br)
QualityIndex - Software (www.datalink.inf.br)QualityIndex - Software (www.datalink.inf.br)
QualityIndex - Software (www.datalink.inf.br)
 
Cờ Tướng - Cờ tàn nghệ thuật và cờ thế giang hồ - Tập 1
Cờ Tướng - Cờ tàn nghệ thuật và cờ thế giang hồ - Tập 1Cờ Tướng - Cờ tàn nghệ thuật và cờ thế giang hồ - Tập 1
Cờ Tướng - Cờ tàn nghệ thuật và cờ thế giang hồ - Tập 1
 
Cờ Tướng - Nủa đường liệt pháo
Cờ Tướng - Nủa đường liệt pháoCờ Tướng - Nủa đường liệt pháo
Cờ Tướng - Nủa đường liệt pháo
 
Cờ Tướng - Thiên phong pháo - 4 phần
Cờ Tướng - Thiên phong pháo - 4 phầnCờ Tướng - Thiên phong pháo - 4 phần
Cờ Tướng - Thiên phong pháo - 4 phần
 
E-commerce services by Hermes NexTec
E-commerce services by Hermes NexTecE-commerce services by Hermes NexTec
E-commerce services by Hermes NexTec
 
Immune system 2
Immune system 2Immune system 2
Immune system 2
 
Cờ Tướng - Cờ tướng khai cuộc cẩm nang
Cờ Tướng - Cờ tướng khai cuộc cẩm nangCờ Tướng - Cờ tướng khai cuộc cẩm nang
Cờ Tướng - Cờ tướng khai cuộc cẩm nang
 
Cờ Tướng - Cờ tướng trung cuộc
Cờ Tướng - Cờ tướng trung cuộcCờ Tướng - Cờ tướng trung cuộc
Cờ Tướng - Cờ tướng trung cuộc
 
Architektura nowoczesnej platformy analitycznej wspierającej kompleksowe zar...
Architektura nowoczesnej platformy analitycznej wspierającej kompleksowe zar...Architektura nowoczesnej platformy analitycznej wspierającej kompleksowe zar...
Architektura nowoczesnej platformy analitycznej wspierającej kompleksowe zar...
 

Similaire à Off Site PCI Expert Panel Review Optimized

Intervention treatment for acs
Intervention treatment for acsIntervention treatment for acs
Intervention treatment for acsKyaw Win
 
Expanding Role of Rivaroxaban Master .pptx
Expanding Role of Rivaroxaban Master .pptxExpanding Role of Rivaroxaban Master .pptx
Expanding Role of Rivaroxaban Master .pptxAhsanRaza759717
 
STEMI – My Approach 2010
STEMI – My Approach 2010STEMI – My Approach 2010
STEMI – My Approach 2010ishakansari
 
Pletaal (cilostazol) utk dokter.ppt (a)
Pletaal (cilostazol) utk dokter.ppt (a)Pletaal (cilostazol) utk dokter.ppt (a)
Pletaal (cilostazol) utk dokter.ppt (a)peyekiwak287
 
STEMI - Cath Lab
STEMI - Cath LabSTEMI - Cath Lab
STEMI - Cath Labishakansari
 
Primary PCI: State of the art. Petr Widimsky
Primary PCI: State of the art. Petr WidimskyPrimary PCI: State of the art. Petr Widimsky
Primary PCI: State of the art. Petr WidimskyChaichuk Sergiy
 
DANISH trial (Cardiology)
 DANISH trial (Cardiology) DANISH trial (Cardiology)
DANISH trial (Cardiology)PRAVEEN GUPTA
 
Acute Stroke Management Handouts Power Point885
Acute Stroke Management Handouts   Power Point885Acute Stroke Management Handouts   Power Point885
Acute Stroke Management Handouts Power Point885MedicineAndHealthNeurolog
 
Espessamento medio intimal carótidal trials
Espessamento medio intimal carótidal trialsEspessamento medio intimal carótidal trials
Espessamento medio intimal carótidal trialsJorge Garcia
 
Low Cardiac Output Synd
Low Cardiac Output SyndLow Cardiac Output Synd
Low Cardiac Output SyndAhmed Shalabi
 

Similaire à Off Site PCI Expert Panel Review Optimized (20)

Intervention treatment for acs
Intervention treatment for acsIntervention treatment for acs
Intervention treatment for acs
 
Thromboectomy trial
Thromboectomy trialThromboectomy trial
Thromboectomy trial
 
Expanding Role of Rivaroxaban Master .pptx
Expanding Role of Rivaroxaban Master .pptxExpanding Role of Rivaroxaban Master .pptx
Expanding Role of Rivaroxaban Master .pptx
 
STEMI – My Approach 2010
STEMI – My Approach 2010STEMI – My Approach 2010
STEMI – My Approach 2010
 
Pletaal (cilostazol) utk dokter.ppt (a)
Pletaal (cilostazol) utk dokter.ppt (a)Pletaal (cilostazol) utk dokter.ppt (a)
Pletaal (cilostazol) utk dokter.ppt (a)
 
STEMI - Cath Lab
STEMI - Cath LabSTEMI - Cath Lab
STEMI - Cath Lab
 
Verheugt F 201109
Verheugt F 201109Verheugt F 201109
Verheugt F 201109
 
PCI & AimRadial 2018 | Use of physiology in ACS - Colin Berry
PCI & AimRadial 2018 | Use of physiology in ACS - Colin Berry PCI & AimRadial 2018 | Use of physiology in ACS - Colin Berry
PCI & AimRadial 2018 | Use of physiology in ACS - Colin Berry
 
Primary PCI: State of the art. Petr Widimsky
Primary PCI: State of the art. Petr WidimskyPrimary PCI: State of the art. Petr Widimsky
Primary PCI: State of the art. Petr Widimsky
 
Cohen MG - AIMRADIAL 2013 - Complex PCI
Cohen MG - AIMRADIAL 2013 - Complex PCICohen MG - AIMRADIAL 2013 - Complex PCI
Cohen MG - AIMRADIAL 2013 - Complex PCI
 
Wivon
WivonWivon
Wivon
 
DANISH trial (Cardiology)
 DANISH trial (Cardiology) DANISH trial (Cardiology)
DANISH trial (Cardiology)
 
Acute Stroke Management Handouts Power Point885
Acute Stroke Management Handouts   Power Point885Acute Stroke Management Handouts   Power Point885
Acute Stroke Management Handouts Power Point885
 
Sort out iii
Sort out iiiSort out iii
Sort out iii
 
Urban P
Urban PUrban P
Urban P
 
Espessamento medio intimal carótidal trials
Espessamento medio intimal carótidal trialsEspessamento medio intimal carótidal trials
Espessamento medio intimal carótidal trials
 
20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia...
20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia...20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia...
20 años de Angioplastia Primaria para el tratamiento del Infarto. Experiencia...
 
09 Cohen aimradial20170922 Ventricular support
09 Cohen aimradial20170922 Ventricular support09 Cohen aimradial20170922 Ventricular support
09 Cohen aimradial20170922 Ventricular support
 
Low Cardiac Output Synd
Low Cardiac Output SyndLow Cardiac Output Synd
Low Cardiac Output Synd
 
Benamer H
Benamer HBenamer H
Benamer H
 

Plus de dwestenberger

G dangas jmc-c lurken
G dangas jmc-c lurkenG dangas jmc-c lurken
G dangas jmc-c lurkendwestenberger
 
Dehmer final--pci without onsite surgery-recent meta-analyses -final
Dehmer final--pci without onsite surgery-recent meta-analyses -finalDehmer final--pci without onsite surgery-recent meta-analyses -final
Dehmer final--pci without onsite surgery-recent meta-analyses -finaldwestenberger
 
Kutcher 11-27-12_final-x
 Kutcher 11-27-12_final-x Kutcher 11-27-12_final-x
Kutcher 11-27-12_final-xdwestenberger
 
Commissioner of health mary o'dowd
Commissioner of health   mary o'dowdCommissioner of health   mary o'dowd
Commissioner of health mary o'dowddwestenberger
 
Dr ken kutscher opening remarks
Dr ken kutscher opening remarksDr ken kutscher opening remarks
Dr ken kutscher opening remarksdwestenberger
 
Final program 11 27-12
Final program 11 27-12Final program 11 27-12
Final program 11 27-12dwestenberger
 

Plus de dwestenberger (8)

Brindis
BrindisBrindis
Brindis
 
G dangas jmc-c lurken
G dangas jmc-c lurkenG dangas jmc-c lurken
G dangas jmc-c lurken
 
Dehmer final--pci without onsite surgery-recent meta-analyses -final
Dehmer final--pci without onsite surgery-recent meta-analyses -finalDehmer final--pci without onsite surgery-recent meta-analyses -final
Dehmer final--pci without onsite surgery-recent meta-analyses -final
 
Kutcher 11-27-12_final-x
 Kutcher 11-27-12_final-x Kutcher 11-27-12_final-x
Kutcher 11-27-12_final-x
 
Dennis presentation
Dennis presentationDennis presentation
Dennis presentation
 
Commissioner of health mary o'dowd
Commissioner of health   mary o'dowdCommissioner of health   mary o'dowd
Commissioner of health mary o'dowd
 
Dr ken kutscher opening remarks
Dr ken kutscher opening remarksDr ken kutscher opening remarks
Dr ken kutscher opening remarks
 
Final program 11 27-12
Final program 11 27-12Final program 11 27-12
Final program 11 27-12
 

Off Site PCI Expert Panel Review Optimized

  • 1. Off Site PCI Expert Panel Review Primary PCI – Development and Outcomes of a New Paradigm of Care Thomas Wharton MD FACC FSCAI Exeter Hospital, Exeter, NH TPWharton
  • 2. Limitations of Thrombolytic Agents  Failure rate: 46% of patients receiving lytics are not reperfused well enough to improve survival (GUSTO).  Recurrent Events: In 20% to 40% of patients.  Strokes: In 1.4% to 6.3%.  Contraindications: Only 25% to 33% of patients with acute M.I. may be eligible for thrombolytic therapy.  Frequent Need for Subsequent Procedures: Cath, PTCA  Are Given “Blindly”: Some patients will be treated unnecessarily, because they have either spontaneously reperfused or been mis-diagnosed. A few of these patients will bleed into the head. TPWharton
  • 3. PAMI-1 STUDY PAMI-1 STUDY 395 randomized lytic eligible pts with AMI :  As compared with t-PA therapy for acute myocardial infarction, immediate PTCA reduced the combined occurrence of nonfatal reinfarction or death, was associated with a lower rate of intracranial hemorrhage, and resulted in similar left ventricular systolic function. NEJM 1993 NEJM 1993
  • 4. 90-Minute Coronary Patency: PAMI vs GUSTO FLOW GRADE PTCA (PAMI) tPA (GUSTO) TIMI 0-1 (no flow) 6% 19% TIMI 2 (slow flow) -- 27% TIMI 3 (brisk flow) 94% 54% TPWharton
  • 5. National Registry of Myocardial Infarction (NRMI)  Only 35% of 241,000 AMI pts were treated with lytics.  These lytic patients frequently needed other procedures:  70.7% underwent cath later before discharge  30.3% “ PTCA  13.3% “ CABG LYTICS (35%) NO LYTICS (65%) Mortality 5.9% 13.0% Major bleeding 2.8% 0.5% TPWharton
  • 6. Primary PCI is Superior to Thrombolytic Therapy for Acute M.I. Pooled data from 10 randomized trials (n=2,606): Primary PTCA tPA p value Mortality 4.4 % 6.5 % 0.02 Death or Reinfarction 7.2 % 11.9 % <0.001 Total Stroke 0.7 % 2.0 % 0.007 Weaver, JAMA 1997;278:2093 Hemorrhagic Stroke 0.1 % 1.1 % TPWharton
  • 7. Primary PCI is Superior to Thrombolytic Therapy for Acute M.I. Brand new pooled data from 21 randomized trials (n=7,739): Primary PCI Lytic Rx p value Mortality 6.9 % 9.3 % 0.0002 Reinfarction 2.4 % 6.8% <0.0001 Total Stroke 1.0 % 2.0 % 0.0004 Hemorrhagic Stroke 0.05 % 1.1 % <0.0001 Combined 8.2 14.3 <0.0001 Keeley, Lancet 2003;361:13-20 TPWharton
  • 8. Broader Applicability of Primary PCI  Primary PTCA is arguably clinically superior to lytic therapy in lytic-eligible patients.* *Weaver, WD, JAMA 1997;278:2093  But even if the therapies were equal, a majority of AMI patients are not candidates for lytic therapy, due to  bleeding contraindications,  shock,  late presentation,  prior bypass surgery,  non-diagnostic EKG’s **Rogers WJ, AJM 1995;99:195  This group is higher-risk than lytic-eligible patients. These patients need an alternative to "morphine and bed rest." TPWharton
  • 9. Primary PCI vs. Other Treatments in Patients Ineligible for Lytic Therapy (MITRA Registry) PTCA Conservative or Fibrinolytic Therapy High Bleeding Non-Diagnostic EKG, 50% Risk (n=337) 50% LBBB, Late Presentation (n=737) 42.3% % of Patients Mortality (%) 24.7% 24.1% 16.4% 8.2% 2.2% 0% 0% PTCA Conservative Mortality Combined Endpoint* Therapy PTCA Lytic PTCA Lytic *death, acute MI, stroke, CHF, angina Zahn, Catheter Cardiovasc Interv 1999;46:127 Zahn, Z Kardiol 1999;88:418 TPWharton
  • 10. Primary PCI in Lytic Eligible Pts that are High Risk (MITRA Registry) High Risk Patients: Age >70, Anterior M.I., Heart Rate > 100 16 PCI Lytics 15.6% 12 9.8% (%) 8 6.7% 4 3.6% 4.1% 3.2% 1.4% 0.5% 0 Death Reinfarction Death or Stroke Re-MI O’Neill, J Invasive Cardiol 1998:10 Suppl A:4A-10A TPWharton
  • 11. New Data From MITRA and MIR German Registries Pooled “real world” outcomes of nearly 10,000 AMI patients in 2 German Registries, 1994-1998: Primary PCI Thrombolysis Mortality 6.4% 11.3% Primary angioplasty was associated with lower mortality in all subgroups both high- andodds ratio 0.54,including pts >75 y.o. 0.67 low-risk, 95% confidence interval 0.43 to As the mortality risk of the subgroup increased, the relative benefit of primary PCI increased. Zahn, JACC 2001;37:1827 TPWharton
  • 12. Advantages of Primary PCI  Can be used in virtually all infarct patients.  Produces TIMI-3 flow over 90% of the time, not 54%.  Does not cause intracranial bleeding.  Reduces need for subsequent procedures (cath, PCI).  Provides important angiographic information: patients who need urgent surgery can be detected early.  Opens vessels as fast or faster.  Can improve prognosis in cardiogenic shock.  Yields a five-fold reduction in mortality in high-risk STEMI pts compared to thrombolytics. TPWharton
  • 13. Profiles of NRMI Registry Hospitals Medical School Affiliation 27.6% Cardiac Surgery 37.6% Cardiac Catheterization Laboratory Rogers WJ, Circulation 1994;90:2103 61.3% TPWharton
  • 14. DANAMI – 2 Trial: Primary PCI vs. Lytics at Hospitals With and Without PCI PCI On Site or After Transfer Thrombolytic Therapy 14.2% 15% 13.7% 12.3% Primary Endpoint (%) (death, MI, CVA) 10% 8.5% 8.0% 6.7% 5% 0% All Patients Presenting to Presenting to Angioplasty Community Centers Hospitals (n = 1,572) (n = 442) (n = 1,129) Andersen, ACC 2002 Presentation TPWharton
  • 15. Prague – 2 Trial PRAGUE-2 Trial (Europe): Prospective randomization of 850 pts to lytic therapy on-site vs. emergency transfer for primary PCI •Thrombolytic Therapy (n = 421) Transfer for PCI (n = 429) 15.2% 30-Day Mortality (%) Death / MI / CVA (%) 10.4% 10% 10% 8.4% 6.0% 0% 0% Immediate transport of all STEMI patients for PCI is now part of the national guidelines of the Czech Republic. Widimsky, European Society of Cardiology, September, 2002 TPWharton
  • 16. DANAMI-2 and PRAGUE-2  The DANAMI-2 and PRAGUE-2 studies established primary PCI as the treatment of choice for all patients presenting with acute STEMI, regardless of where they initially present.  All such patients at hospitals without PCI should be transferred immediately directly into the cath lab of a PCI center, ideally with an “indoor-outdoor” time of <30 minutes. TPWharton
  • 17. Delay and Mortality of Primary PCI After T ransfer: PTCA On Site (n=9,311) PTCA After Transfer (n=1,307) 6.0h 6.0 10% 7.7% 3.7h Time (hours) Mortality (%) 4.0 5.0% 5% 2.0 0.0 0% Time From Death AMI Onset to PTCA (In-Hospital) Transfer of acute MI patients to a surgical institution involves risk and delay, and is associated with worse outcomes than PCI on site. Tiefenbrunn, Circulation 1997:96:I-531 TPWharton
  • 18. Guidelines Evolve as Medical Care Evolves From the 1988 PCI Guidelines re Surgical Backup for PCI:  “An experienced cardiovascular surgical team should be available within the institution for all angioplasty procedures,” and “there should be no exception to this requirement.”  “All arrangements requiring transportation of patients to off-site surgical facilities fail to meet the necessary standards of care exercised by prudent physicians and cannot be condoned.” TPWharton
  • 19. Off Site PCI Expert Panel Review without onsite surgery Primary PCI – ^ Development and Outcomes n even newer of a New Paradigm of Care ! a Thomas Wharton MD FACC FSCAI Exeter Hospital, Exeter, NH TPWharton
  • 20. Primary Angioplasty for the Treatment of Acute Myocardial Infarction: Experience at Two Community Hospitals Without Cardiac Surgery Thomas P. Wharton, Jr., MD, FACC, Nancy Sinclair McNamara, RN, BSN, Frank A. Fedele, MD, FACC, Mark I. Jacobs, MD, FACC, Alan R. Gladstone, MD, Erik Funk, MD, FACC Exeter and Portsmouth, New Hampshire 506 consecutive pts:  “Primary angioplasty in patients with AMI can be performed safely and effectively in community hospitals without on-site cardiac surgery when rigorous program criteria are established.” JACC April, 1999 JACC April, 1999
  • 21. 2001 ACC/AHA Guidelines for Off-Site PCI The 2001 ACC/AHA guidelines designated primary PCI at hospitals with off-site cardiac surgery as Class IIb: “Usefulness/efficacy is less well established by evidence/opinion,” provided that:  > 36 procedures/yr are performed at such hospitals,  by higher-volume operators (>75 procedures/yr),  within 90 ± 30 min of admission,  with a proven plan for rapid access to a cardiac surgical center. JACC 2001;37:2215 TPWharton
  • 22. ACC/AHA 2001 PCI Guidelines ACC/AHA 2001 PCI Guidelines TPWharton
  • 23. 2001 ACC/AHA Guidelines for Off-Site PCI  This Committee also designated non-emergent PCI as Class III: stated that their Class III: “Not useful/effective, and in some cases may be harmful.”  This classification was based on “consensus opinion of experts,” thus was not evidence-based (Level of Evidence C). TPWharton
  • 24.
  • 25. CRITICAL PATHWAY: PRIMARY PCI AT HOSPITALS WITH OFF-SITE CARDIAC SURGICAL BACKUP PRE-HOSPITAL: Suspected AMI. Exeter Hospital Diagnostic EMS paramedic level of care, aspirin, IV line, sublingual NTG, 12-lead ST elevation ©2005 Wharton, Sinclair ECG transmitted to ED, heparin. ED physician calls interventional No diagnostic ST Elevation cardiologist and cath team. EMERGENCY DEPARTMENT: AMI diagnosed. >30 minutes of uncontrolled ischemic pain with positive serum markers and/or ECG with >1mm of ST deviation or LBBB. Call interventional cardiologist and cath team. EMERGENCY DEPARTMENT TREATMENT: ASA (if not given by EMS), heparin or enoxaparin, IV beta blocker, nitropaste, morphine, second IV line. Consider platelet GP IIb/IIIa inhibitor, clopidogrel. Treat pain, CHF, shock, arrhythmias. EMERGENCY TRANSFER to interventional / surgical hospital. CATH LAB Activate Emergency Transfer Protocol No AVAILABLE? with "indoor-outdoor" ED time goal of 45 minutes. Consider IABP (at capable hospitals) if hemodynamically unstable. Yes Consent, transport to cath lab. CARDIAC CATH LAB: PRIMARY PCI Arterial sheath; venous sheath if unstable or heart of IRA only. block, IABP if in shock or hemodynamically unstable, pacer as needed. Coronary angiography. Yes No EMERGENCY CABG indicated DETERMINE with or without PCI: TIMI 3 FLOW REVASCULARIZATION CABG Activate Emergency Transfer IN IRA? STRATEGY Protocol. Primary PCI RISK STRATIFICATION* Medical AND MANAGEMENT therapy PRIMARY PCI *Clinical and angiographic Not of IRA only. Monitor ACT, GP IIb/IIIa inhibitor. low risk: Age <70, 1-2 v low risk Left ventriculogram. Consider right heart disease, EF >45%, no CHF Low risk catheterization, IABP, pacer if unstable. or arrhythmias, good PCI result. Admit to interventional unit. Standard CCU care. Fast-track cardiac rehabilitation; Target discharge on MEDICAL THERAPY target discharge on hospital day hospital day 4-5, ASA, GP IIb/IIIa inhibitor, beta blocker, ACE inhibitor 3 without pre-discharge ETT. consider ETT. or ARB, statin, clopidogrel load and maintentance. Return to work at 2 weeks. Elective CABG if indicated. Smoking cessation,risk factor identification and modification, cardiac rehabilitation. DISCHARGE; cardiac rehab phase II; ETT and lipid profile at 4 wks.
  • 26. Circulation November 2005 Circulation November 2005 T Wharton, Exeter Hospital
  • 27. Primary PCI in 500 high-risk pts at 19 off-site hospitals was compared to pts transferred after presentation to non-PCI hospitals: “On-site PA and transfer groups had similar 30-day outcomes, and more rapid reperfusion for on-site PA.” JACC 2004 JACC 2004 TPWharton
  • 28.  “The study by Wharton et al. is extremely relevant because currently there is great debate regarding the appropriateness of performing primary PCI at hospitals without on-site surgery. . .”  “This study documents that superb outcomes can be achieved at hospitals that do not offer on-site cardiac surgery. . .” JACC 2004 JACC 2004 TPWharton
  • 29.  “I believe the data presented by Wharton et al. provide sufficient evidence to revise these guidelines to provide a class IIa indication (weight of evidence/opinion is in favor of usefulness/efficacy) for primary PCI at hospitals with catheterization laboratories but without on-site surgery.” JACC 2004 JACC 2004 TPWharton
  • 30. 2005 Guidelines for PCI Off-Site  Nevertheless the 2005 Guidelines Committee maintained its Class IIb indication for Primary PCI at hospitals without on-site cardiac surgery.  The 2005 Guidelines Committee also maintained its Class III indication for elective PCI at such hospitals, and unfortunately introduced new and very inflammatory language, arguably without valid justification, not citing a large amount of new literature: “Performing elective PCI in a setting without immediately available onsite cardiac surgery potentially compromises patient safety and is not recommended.” TPWharton
  • 31. TPW Presentation on Guidelines at ACC 2006 “In view of the rapidly accumulating evidence of safety and efficacy, and no relevant evidence of harm reported to date (the JAMA Medicare claims-coding article notwithstanding), strong consideration should be given now to upgrading the Guidelines indication for non-emergent PCI from Class III to Class IIb at centers with off-site backup that can meet rigorous qualifications.” TPWharton
  • 32. TPW Presentation on Guidelines at ACC 2006 An audience member made the following observation at my presentation at an ACC Guidelines session in 2006: “Since the Guidelines Writing Committee’s conclusions carry so much weight, and have such a powerful influence on 3rd party payors, state regulators, and litigation attorneys, the Writing Committee has a profound responsibility to fairly consider, fairly interpret, and rapidly update all of the available information in this vital and growing field.” TPWharton
  • 33. Critical Pathways in Cardiology June 2005 Critical Pathways in Cardiology June 2005
  • 34. 1 Gathered facts and trends on prevalence of PCI without on-site surgery 2 Reviewed existing guidelines worldwide on PCI without onsite surgery 3 Reviewed literature related to PCI without on-site surgery much more comprehensively than did the 2005 ACC/AHA Guidelines 4 Defined the best practice methods for PCI without on-site surgery 5 Made recommendations on the role of PCI without on-site surgery Catheterization and Cardiovascular Interventions March, 2007 Catheterization and Cardiovascular Interventions March, 2007
  • 35. Patient Selection Criteria – PRIMARY PCI Patient Selection Criteria for Angioplasty and Emergency Aortocoronary Bypass at Hospitals Without On-Site Cardiac Surgery Avoid intervention in hemodynamically stable patients with: • Significant (> 60%) stenosis of an unprotected Left Main (LM) coronary artery upstream from an acute occlusion in the left coronary system that might be disrupted by the angioplasty catheter • Extremely long or angulated infarct-related lesions with TIMI grade 3 flow • Infarct-related lesions with TIMI Grade 3 flow in stable patients with three vessel disease • Infarct-related lesions of small or secondary vessels • Lesions in other than the infarct artery Transfer for emergent aortocoronary bypass surgery patients with: • High-grade residual left main or multivessel coronary disease and clinical or hemodynamic instability o After angioplasty or occluded vessels o Preferably with intraaortic balloon pump support Table 16: American College of Cardiology/ American Heart Association Percutaneous Coronary Intervention Guidelines. Adapted with permission from Wharton TP Jr, McNamara NS, Fedele FA, Jacobs MI, Gladstone AR, Funk EJ. Primary angioplasty for the treatment of acute myocardial infarction: experience at two community hospitals without cardiac surgery. Journal of American College of Cardiology 1999; 33: 1257-65. Catheterization and Cardiovascular Interventions March, 2007 Catheterization and Cardiovascular Interventions March, 2007 TPWharton
  • 36. Catheterization and Cardiovascular Interventions March, 2007 Catheterization and Cardiovascular Interventions March, 2007 TPWharton
  • 37. Catheterization and Cardiovascular Interventions March, 2007 Catheterization and Cardiovascular Interventions March, 2007 TPWharton
  • 38. Catheterization and Cardiovascular Interventions March, 2007 Catheterization and Cardiovascular Interventions March, 2007 TPWharton
  • 39. Catheterization and Cardiovascular Interventions March, 2007 Catheterization and Cardiovascular Interventions March, 2007 TPWharton
  • 41. Case Presentation • Two weeks before Hurricane Sandy this 59 y.o. lady lost her adult son tragically. • Two days after the son’s death, she collapsed at home. • Her husband, not knowing CPR, called 911 and ran to the neighbor’s house. • The neighbor ran over and started CPR. • EMS administered 3 shocks for ventricular fibrillation (VF), epinephrine boluses, performed intubation, and transmitted EKG to ED. TPWharton
  • 42. Case Presentation TPWharton
  • 43. Case Presentation • After 30 minutes in the field, a pulse was felt. • On arrival in the ED she was unresponsive, fixed pupils, with thready carotids and no peripheral pulse. • A countershock was required for recurrent VF. • The Arctic Sun therapeutic cooling system was applied in the E.D. TPWharton
  • 44. Arctic Sun Therapeutic Cooling Device TPWharton
  • 45. Arctic Sun Therapeutic Cooling Device TPWharton
  • 46. Updated 2005 AHA Guidelines for CPR Class II: Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment. IIa. Weight of evidence/opinion is in favor of usefulness/efficacy. IIb. Usefulness/efficacy is less well established by evidence/opinion. Circulation 2005; 112:IV-206 – IV-211 TPWharton
  • 47. Case Presentation • She was then taken to the Cath Lab, shocky and very acidotic, on 2 pressors and the cooling device. • On arrival at the cath lab she developed pulseless electrical activity (PEA). • The Lucas cardiac compression device was applied, with a radiolucent back plate to allow fluoroscopy. This produced an excellent pulse. TPWharton
  • 48. LUCAS External Compression CPR TPWharton
  • 49. LUCAS External Compression CPR TPWharton
  • 50. Case Presentation • After bifemoral access we were able to use cranially-angluated fluoroscopy to position an intraaortic balloon while on the Lucas CPR device. • On the balloon pump and pressors, we were able to discontinue the Lucas CPR device. • Severe metabolic acidosis responded only poorly to aggressive treatment. • She remained unresponsive, pressor dependent. TPWharton
  • 51. Case Presentation (Coronary angiography was shown which demonstrated a totally occluded proximal LAD artery with no antegrade flow and no collateralizaion, successfully recanalized with PCI/stenting.) TPWharton
  • 52. Case Presentation • On reperfusion she developed incessant VF, requiring 7 countershocks, amiodarone boluses, empiric Mg++ and K+ IV. • She remained pressor and balloon pump dependent, acidotic, unresponsive, cardiac output 1.6 L/m, wedge pressure 30mmHg, no urine. • After 18 h and the addition of dobutamine, her hemodyamics began to improve. • After 24 hours she was re-warmed. TPWharton
  • 53. Case Presentation TPWharton
  • 54. Case Presentation TPWharton
  • 55. Case Presentation • Pressors were weaned, IABP removed on day 3, extubated day 6. • Her echo EF had improved to 50-55% with minimal anterior wall hypokinesis. • By extubation on day 7 she was completely alert, very talkative. • One of the first things she said moments after extubation was that she had visited her deceased son; that he was “with God;” but God told her “get back home, I don’t want you yet.” TPWharton
  • 56. Case Presentation TPWharton
  • 57. Case Presentation • This extraordinary outcome demonstrates what a flawless “chain of survival” can accomplish, from EMS in the field, thru ED, thru respiratory and ICU nursing care. • In particular, this outcome would not have been possible without expert 24/7 PCI available nearby, at the point of first patient contact. • She is now home, enjoying Thanksgiving with her family, completely mentally intact and with excellent cardiac function. TPWharton
  • 58. Case Presentation • The door-to-defibrillation-to-cooling-to- Lucas CPR-to-balloon pump time (D-2-D-2-C-2-L-2-IABP time) was 86 minutes. • The LAD coronary was opened in 18m more. • Her brain was very poorly perfused for about 2 hours. • Locally available immediate primary PCI meant the difference between life and death in this woman. TPWharton
  • 59. Case Presentation • One of the cath lab staff observed after the procedure—and this was his own idea— “Ya know, Dr. Wharton, if we didn’t do so many stable elective patients in this lab, we wouldn’t have had the experience to be able to perform nearly so well in this case!” TPWharton
  • 60. 2011 Guidelines for PCI Off-Site TPWharton
  • 61. 2011 Guidelines for PCI Off-Site 4.8. PCI in Hospitals Without On-Site Surgical Backup: Recommendations CLASS IIa 1. Primary PCI is reasonable in hospitals without onsite cardiac surgery, provided that appropriate planning for program development has been accomplished. CLASS IIb 1. Elective PCI might be considered in hospitals without on-site cardiac surgery, provided that appropriate planning for program development has been accomplished and rigorous clinical and angiographic criteria are used for proper patient selection. Better Late than Never !! TPWharton
  • 62. Corazon Materials Related to Economic Quality Impact of Avoidance of Staged PCI Procedures © Corazon, Inc. All rights reserved.
  • 63. PCI-Staged vs. Same Setting of Care Payor Cost Avoidance Scenario $7302 per case cost Sample based on 2010 Medicare avoidance $7+ Million cost avoidance with Statewide Sample •Hospital component for PCI based on CMS split of case volume across DRGs 246-251 •Physician Pro-fee for dx cath based on CMS left heart cath & PCI blended payment rate based on 1.4 stents/case •Transport based on State ground rates + 10 miles & a blend of Advanced Life Support levels © Corazon, Inc. All rights reserved. © Corazon, Inc. All rights reserved. 64

Notes de l'éditeur

  1. We agree with Ryan: not every interventionalist and not every hospital should do PCI.
  2. We agree with Ryan: not every interventionalist and not every hospital should do PCI.
  3. We agree with Ryan: not every interventionalist and not every hospital should do PCI.
  4. We agree with Ryan: not every interventionalist and not every hospital should do PCI.